谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David Sallman,Monzr Al Malki,Adam Asch,Eunice Wang,Joseph Jurcic,Terrence Bradley, Ian Flinn,Daniel Pollyea,Suman Kambhampati,Tiffany Tanaka,Joshua Zeidner,Guillermo Garcia-Manero,Deepa Jeyakumar,Lin Gu,Anderson Tan,Mark Chao,Carol O'Hear,Indu Lal,Paresh Vyas,Naval Daver

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览31
暂无评分
关键词
MDS, myelodysplastic syndromes, magrolimab, azacitidine, CD47, TP53, Phase I
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要